Literature DB >> 20961669

[Serological markers in immigrant and Spanish pregnant women in Granada].

Antonio Sampedro1, Pablo Mazuelas, Javier Rodríguez-Granger, Eva Torres, Alberto Puertas, José María Navarro.   

Abstract

INTRODUCTION: Female immigration from less developed countries into Spain has grown in number over the years, and could contribute to changing the prevalence of routine serological markers in pregnant women.
MATERIAL AND METHODS: From April 2007 until May 2008 we studied the prevalence of serum antibodies against Treponema pallidum, Toxoplasma gondii, rubella virus, human immunodeficiency virus (HIV 1/2), and hepatitis B virus (HBV) in samples from 4,171 immigrant and Spanish pregnant women in Granada.
RESULTS: The seroprevalence of toxoplasmosis in pregnant immigrants was higher than in non-immigrants (44% vs. 14.4%). The overall prevalence against rubella was 97.3%. Sub-Saharan and North African women showed the lowest prevalence (88% and 89%). The prevalence of HBsAg was higher in immigrants than in Spanish women (2.6% vs. 0.4%), and especially high among the Eastern European (6.9%) and Asian (8.1%) pregnant women. The seroprevalences of HIV (0.9% vs. 0.1%) and syphilis (TPHA) (3.5% vs. 0.07%), were higher in immigrants. Seroprevalence against T. pallidum was higher among Eastern European (11.5%) and Latin-American (3.5%) women, whereas sub-Saharan (11.8%) and North African (1%) women showed the highest anti-HIV prevalence.
CONCLUSION: Hepatitis B, anti-HIV, syphilis, and antibodies against T. gondii are found more frequently in immigrants than in Spanish pregnant women, whereas rubella protection in Spanish women is higher than immigrant pregnant women.
Copyright © 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961669     DOI: 10.1016/j.eimc.2010.04.007

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  5 in total

Review 1.  Hispano-Americans in Europe: what do we know about their health status and determinants? A scoping review.

Authors:  Maria Roura; Andreu Domingo; Juan M Leyva-Moral; Robert Pool
Journal:  BMC Public Health       Date:  2015-05-07       Impact factor: 3.295

2.  Prevalence of chronic infections and susceptibility to measles and varicella-zoster virus in Latin American immigrants.

Authors:  Yves Jackson; Lilian Santos; Isabelle Arm-Vernez; Anne Mauris; Hans Wolff; François Chappuis; Laurent Getaz
Journal:  Infect Dis Poverty       Date:  2016-05-11       Impact factor: 4.520

3.  Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.

Authors:  Ángeles Ruiz-Extremera; María Del Mar Díaz-Alcázar; José Antonio Muñoz-Gámez; Marta Cabrera-Lafuente; Estefanía Martín; Rosa Patricia Arias-Llorente; Pilar Carretero; José Luis Gallo-Vallejo; Francisca Romero-Narbona; M A Salmerón-Ruiz; Clara Alonso-Diaz; Rafael Maese-Heredia; Lucas Cerrillos; Ana María Fernández-Alonso; Carmen Camarena; Josefa Aguayo; Miguel Sánchez-Forte; Manuel Rodríguez-Maresca; Alfredo Pérez-Rivilla; Rosa Quiles-Pérez; Paloma Muñoz de Rueda; Manuela Expósito-Ruiz; Federico García; Fernando García; Javier Salmerón
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

4.  Screening for Trypanosoma cruzi infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology.

Authors:  María Velasco; Luis Andrés Gimeno-Feliú; Israel Molina; Joaquín Salas-Coronas; Ivan Solà; Begoña Monge-Maillo; Diego Torrús-Tendero; Joan Caylà; Ena Niño de Guzmán; Jl Pérez Arellano; Jose A Pérez-Molina
Journal:  Euro Surveill       Date:  2020-02

5.  Global burden of maternal and congenital syphilis in 2008 and 2012: a health systems modelling study.

Authors:  N Saman Wijesooriya; Roger W Rochat; Mary L Kamb; Prasad Turlapati; Marleen Temmerman; Nathalie Broutet; Lori M Newman
Journal:  Lancet Glob Health       Date:  2016-08       Impact factor: 26.763

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.